Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

BTIG starts iCAD at buy; PT $25

BTIG initiated coverage of iCAD (NASDAQ:ICAD) with a “buy” rating and a price target of $25. The stock closed at $19.35 on March 22. iCAD is a medical technology company focused on cancer care, offering both cutting...

March 23, 2021

Markets

Cantor starts Eledon Pharma at OW; PT $25

Cantor Fitzgerald launched coverage of Eledon Pharmaceuticals (NASDAQ:ELDN) with an “overweight” rating and $25 price target. The stock closed at $13.65 on March 22. Eledon is focused on developing AT-1501, which is an...

March 22, 2021

Markets

HCW starts MiMedx at buy; PT $20

H.C. Wainwright launched coverage of MiMedx Group (NASDAQ:MDXG) with a “buy” rating and $20 price target. The stock closed at $8.81 on March 18. MiMedx is a wound care industry leader commercializing placental...

March 19, 2021

Markets

WB cuts Acutus Medical to market perform

William Blair downgraded Acutus Medical (NASDAQ:AFIB) to “market perform,” saying “early-stage growing pains lead to lower than expected guidance.” The stock closed at $16.83, down $2.23, on March 18. Analyst Margaret...

March 19, 2021

Markets

SVB Leerink starts Merus at OP; PT $33

SVB Leerink launched coverage of Merus NV (NASDAQ:MRUS) with an “outperform” rating and $33 price target. The stock closed at $22.04 on March 15. Merus is focused on developing novel bispecific and trispecific...

March 16, 2021

Markets

Maxim starts Oncorus at buy; PT $35

Maxim Group initiated coverage of Oncorus (NASDAQ:ONCR) with a “buy” rating and price target of $35. The stock closed at $16.39 on March 15. Oncorus is developing oncolytic viral (OV) immunotherapies for solid tumors...

March 16, 2021

Markets

SVB Leerink ups Solid Biosciences to OP from MP; PT to $15 from $3

SVB Leerink upgraded Solid Biosciences (NASDAQ:SLDB) to “outperform” from “market perform” and raised its price target to $15 from $3, citing the first functional data for the company’s microdystrophin gene...

March 16, 2021

Markets

Canaccord ups TransMedics PT to $79 from $46

Canaccord Genuity raised its price target for TransMedics Group (NASDAQ:TMDX) to $79 from $46, saying the company has the “technology that will become the standard of care for organ transplant and in the process...

March 15, 2021

Markets

BTIG starts Seelos Therapeutics at buy; PT $14

BTIG initiated coverage of Seelos Therapeutics (NASDAQ:SEEL) with a “buy” rating and $14 price target. The stock closed at $3.04 on March 11. Seelos’ lead clinical candidate, SLS-002, is an intranasally delivered...

March 12, 2021

Markets

WB ups Selecta Biosciences to outperform

William Blair upgraded Selecta Biosciences (NASDAQ:SELB) to “outperform,” citing multiple upcoming positive risk/reward catalysts for the company. The stock closed at $3.90 on March 11. The company’s ImmTOR platform...

March 12, 2021

Markets

SVB Leerink starts Aldeyra Therapeutics at OP; PT $22

SVB Leerink launched coverage of Aldeyra Therapeutics (NASDAQ:ALDX) with an “outperform” rating and $22 price target. The stock closed at $12.07 on March 11. Two of the company’s lead investigational compounds...

March 12, 2021

Markets

Maxim doubles Entera Bio PT to $10 from $5 on new data; shares soar

Maxim Group raised its price target for Entera Bio (NASDAQ:ENTX) to $10 from $5, citing updated data from an ongoing Phase 2 trial of oral parathyroid hormone candidate, EB613, in osteoporosis. At midday on March 11...

March 11, 2021

Markets

Maxim starts MediciNova at buy; PT $15

Maxim Group launched coverage of MediciNova (NASDAQ:MNOV) with a “buy” rating and $15 price target. The stock closed at $5.68 on March 9. MediciNova is developing MN-166 for neurodegenerative diseases, glioblastoma...

March 10, 2021

Markets

Cantor starts Auxly Cannabis at OW; PT $85 cents (Canadian)

Cantor Fitzgerald initiated coverage of Auxly Cannabis Group (TSXV:XLY) with an “overweight” rating and price target of 85 cents (Canadian). The stock closed at 36 cents on March 9. Auxly is the number one player in...

March 10, 2021

Markets

Maxim starts Panbela Therapeutics at buy; PT $8

Maxim Group launched coverage of Panbela Therapeutics (NASDAQ:PBLA) with a “buy” rating and $8 price target. The stock closed at $4.17 on March 9. The company’s polyamine metabolic inhibitor drug candidate, SBP...

March 10, 2021

Markets

Cantor starts NexImmune at OW, PT $35

Cantor Fitzgerald launched coverage of NexImmune (NASDAQ:NEXI) with an “overweight” rating and price target of $35. The stock closed at $20.63 on March 8. NexImmune is developing a novel approach in cancer immunotherapy...

March 9, 2021

Markets

BTIG starts Talis Biomedical at buy; PT $18

BTIG initiated coverage of point-of-care diagnostics company, Talis Biomedical, (NASDAQ:TLIS) with a “buy” rating and $18 price target. The stock closed at $12.95 on March 8. “Consistent with our checks with KOLs … we...

March 9, 2021

Markets

Cantor starts Akebia Therapeutics at OW; PT $8

Cantor Fitzgerald launched coverage of Akebia Therapeutics (NASDAQ:AKBA) with an “overweight” rating and $8 price target. The stock closed at $3.41 on March 5. The company’s lead asset, vadadustat, is an oral hypoxia...

March 8, 2021

Markets

BTIG starts OncoSec Medical at buy; PT $10

BTIG initiated coverage of OncoSec Medical (NASDAQ:ONCS) with a “buy” rating and $10 price target. The stock closed at $5.23 on March 5. OncoSec is working to develop safe versions of the powerful immune stimulator...

March 8, 2021

Markets

Echelon starts Diagnos at speculative buy; PT 85 cents (Canadian)

Echelon Capital Markets initiated coverage of Diagnos (TSXV:ADK) with a “speculative buy” rating and price target of 85 cents (Canadian). The stock closed at 60 cents on March 4. ADK is a commercial-stage artificial...

March 5, 2021

Markets

Canaccord ups TransMedics PT to $46 from $20

Canaccord Genuity raised its price target for TransMedics (NASDAQ:TMDX) to $46 from $20, predicting 2021 would be transformational with two potential product approvals and a roll-out of an enhanced support model. The...

March 3, 2021

Markets

Maxim starts NLS Pharmaceutics at buy; PT $8

Maxim Group launched coverage of NLS Pharmaceutics AG (NASDAQ:NLSP) with a “buy” rating and $8 price target. The stock closed at $2.83 on March 2. NLS is developing Quilience for narcolepsy and Nolazol for ADHD; both...

March 3, 2021

Subscribe